The city of Renton, Washington, currently has 3 active clinical trials seeking participants for Diabetes research studies.
A Study of CT-868 in Type 1 Diabetes Mellitus
Recruiting
This study will evaluate the changes in glycemic control in overweight and obese adults with Type 1 Diabetes Mellitus after receiving CT-868 for 16 weeks. The effectiveness and safety of CT-868 will be compared to placebo. All participants will continue with their standard diabetes care using either an insulin pump (CSII) or multiple daily injections (MDI). Alongside their designated treatment, participants will receive guidance on managing their diabetes, including monitoring blood glucose leve... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/19/2023
Locations: Carmot Therapeutics Investigational Site 109, Renton, Washington
Conditions: Overweight, Obese, Type 1 Diabetes Mellitus
Enhance Study: Evaluation of Accuracy and Safety of the Eversense CGM System With Enhanced Features
Recruiting
A Prospective, Multicenter Evaluation of Accuracy and Safety of the Eversense CGM System with Enhanced Features. The purpose of this clinical investigation is to evaluate the accuracy of the Eversense 524 Continuous Glucose Monitoring System (Eversense 524 CGM System) and ROME CGM System with next generation feature enhancements compared to reference glucose measurements in adults 18 years of age and older with diabetes. The investigation will also evaluate safety of the Eversense 524 CGM System... Read More
Gender:
All
Ages:
14 years and above
Trial Updated:
04/24/2023
Locations: Rainier Clinical Research Center, Renton, Washington
Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
CGMIS 48-hour Feasibility Study
Recruiting
This is a single center, single arm non-randomized study of 48-hour CGMIS wear duration incorporating two meal-challenge tests to explore the performance of a single insertion combined glucose-sensing insulin delivery cannula.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
09/28/2022
Locations: Rainier Clinical Research Center, Renton, Washington
Conditions: Type1diabetes